Management focus is on a strong balance sheet
20/11/23 -"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."
Pages
52
Language
English
Published on
20/11/23
You may also be interested by these reports :
07/12/23
Sanofi has unveiled its R&D plans today in an effort to convince investors of their effectiveness, as the share price hasn’t yet fully recovered ...
05/12/23
With the >$3bn Carmot Therapeutics acquisition, Roche has entered the race in the burgeoning anti-obesity market. While, against the backdrop of ...
05/12/23
Takeaways from our third & fourth Materials Reverse Roadshow Day with Sika, Siegfried, Wacker and Bucher
04/12/23
Bayer (Buy, Germany) has entered the Alphavalue top 20 chart of companies with the strongest upsides. Being number 12 in this hit parade, the company ...